GleamWall
中文EN

GLSI Greenwich LifeSciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1799788 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-27.9%
TTM EPS YoY-14.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-107,371.7%
ROA-481.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets129.6%
Debt / equity—
Current ratio0.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.55x
Accruals ratio-217.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$17.22M$15.48M
SG&A expense$2.23M$2.16M
Operating income-$19.45M-$17.64M
Net income-$19.36M-$17.41M
EPS (basic)-1.43-1.34
EPS (diluted)-1.43-1.34
Weighted avg. shares (diluted)13.53M13.01M
Balance sheet
Cash & equivalents$6.18M$4.09M
Current assets$6.18M$4.09M
Intangibles—$1,779
Total assets$6.18M$4.09M
Current liabilities$5.82M$3.19M
Total liabilities$5.82M$3.19M
Shareholders' equity$353,217$908,626
Shares outstanding14.30M13.15M
Cash flow statement
Operating cash flow-$9.91M-$7.27M
Financing cash flow$12.00M$4.37M
Stock-based compensation$6.80M$7.25M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.